Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06111014 · ClinicalTrials.gov registry record · Phase 3
Continuation Study for Latozinemab
A Phase 3 study, sponsored by Alector.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT06111014: Clinical Trial Phase 3 study, sponsored by Alector.
NCT06111014 is a Phase 3 study that was terminated before completion, run by Alector. The registered enrollment target is 17 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06111014, a Phase 3 study, was terminated before completion, sponsored by Alector.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
Primary Outcome
Number of participants receiving latozinemab
Interventions
- DRUG Latozinemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2026-01-07 |
| Phase | Phase 3 |
Why NCT06111014 stopped before completion
NCT06111014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Latozinemab is the first listed.
NCT06111014 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06111014 about?
NCT06111014 is a clinical study titled "Continuation Study for Latozinemab". Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
What is the current status of trial NCT06111014?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2023-12-08. Estimated completion is 2026-01-07.
What interventions are being tested in trial NCT06111014?
The interventions under investigation include: Latozinemab (DRUG).
Who is sponsoring clinical trial NCT06111014?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06111014's enrollment target sits among peer trials
17 1971st of 2000 higher than 27 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI